Published in J Korean Med Sci on October 16, 2015
Lessons from the withdrawal of rofecoxib. BMJ (2004) 3.33
The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA (1999) 3.24
Developing the Sentinel System--a national resource for evidence development. N Engl J Med (2011) 2.93
Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf (2010) 2.57
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther (1995) 2.41
A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health (2014) 2.32
A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy. Soc Sci Med (2005) 1.49
Understanding the rapid increase in life expectancy in South Korea. Am J Public Health (2010) 1.32
Management of thalidomide toxicity. J Support Oncol (2004) 1.17
Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC Med (2015) 0.99
Health avatar: an informatics platform for personal and private big data. Healthc Inform Res (2014) 0.81
Current Clinical Status of Telehealth in Korea: Categories, Scientific Basis, and Obstacles. Healthc Inform Res (2015) 0.78